ChengDa Pharmaceuticals Balans Gezondheid
Financiële gezondheid criteriumcontroles 6/6
ChengDa Pharmaceuticals has a total shareholder equity of CN¥2.2B and total debt of CN¥0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CN¥2.4B and CN¥162.4M respectively. ChengDa Pharmaceuticals's EBIT is CN¥33.7M making its interest coverage ratio -0.9. It has cash and short-term investments of CN¥1.2B.
Belangrijke informatie
0%
Verhouding schuld/eigen vermogen
CN¥0
Schuld
| Rente dekkingsratio | -0.9x |
| Contant | CN¥1.18b |
| Aandelen | CN¥2.23b |
| Totaal verplichtingen | CN¥162.38m |
| Totaal activa | CN¥2.40b |
Recente financiële gezondheidsupdates
Geen updates
Recent updates
ChengDa Pharmaceuticals Co., Ltd.'s (SZSE:301201) 42% Price Boost Is Out Of Tune With Earnings
Oct 08
There's Reason For Concern Over ChengDa Pharmaceuticals Co., Ltd.'s (SZSE:301201) Massive 42% Price Jump
Oct 08ChengDa Pharmaceuticals (SZSE:301201) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Sep 03ChengDa Pharmaceuticals (SZSE:301201) Will Pay A Smaller Dividend Than Last Year
Jul 05Analyse van de financiële positie
Kortlopende schulden: 301201's short term assets (CN¥1.5B) exceed its short term liabilities (CN¥157.7M).
Langlopende schulden: 301201's short term assets (CN¥1.5B) exceed its long term liabilities (CN¥4.6M).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: 301201 is debt free.
Schuld verminderen: 301201 has no debt compared to 5 years ago when its debt to equity ratio was 35.7%.
Schuldendekking: 301201 has no debt, therefore it does not need to be covered by operating cash flow.
Rentedekking: 301201 has no debt, therefore coverage of interest payments is not a concern.